MiRNAs are a large group of small non-coding RNAs that play vital roles in various biological processes [
1]. MiRNAs regulate the expression of a variety of target genes and their dysregulation is closely related to the development of diseases including cancer. The abnormal expression of miRNAs in cancer contributes to almost every field of tumor pathology [
2,
3], including drug resistance [
4], which remains a major obstacle to effective therapy of patients [
5]. The multi-chemoresistance property differs dramatically among the cancer patients, even in the different cancer lesions of a single patient [
6]. Despite of intensive efforts, our knowledge of the multi-chemoresistance of cancers remains very poor due to the diverse mechanisms that induce the multi-chemoresistance [
7,
8]. To date, the emerging studies have been focused on the role of miRNAs in the occurrence of chemoresistance in different cancers. The prominent examples for bladder cancer chemoresistance are miR-181, miR-199a-5p, miR-30d [
9] and miR-193a-3p [
5,
10]. In hepatocellular carcinoma (HCC) cells, miR-193a-3p contributes to the 5-FU resistance regulated by the DNA methylation in particular
via repressing SRSF2 expression [
10]. In addition, overexpressed miR-21 in colorectal cancer tissues contributes to the resistance to 5-FU [
11]. The expression of miR-130a is higher in SKOV3/DDP, and suppression of miR-130a could conquer the cisplatin resistance by targeting the MDR1/P-gp pathway [
12]. The miR-140 participates in the drug resistance to osteosarcoma (OS) xenografts by decreased cell proliferation via G- and G2-phase arrest [
13].
The miR-34 family members are down-regulated in a variety of cancers and the expression of miR-34 is directly regulated by the transcription factor p53 [
14‐
16]. Moreover, miR-34a negatively regulates the Delta-like ligand 1 (DLL1) of the Notch pathway and thus down-regulates cell proliferation by inducing apoptosis and neural differentiation in medulloblastoma cells. In gliomas, miR-34a down-regulates c-Met and CDK6, suggesting that miR-34a provides a therapeutic biomarker for brain tumors [
17]. Furthermore, miR-34a-5p, derived from miR-34a, has been found to prevent cell migration and invasion [
18‐
21], which indicated that miR-34a-5p might involve in inhibiting tumor development.
OS is the most common malignant primary bone tumor which is frequently occurred in children and adolescents [
22,
23], and the mechanism for the OS chemoresistance remains limited. In the present study, we set up a RNA-seq assay and identified several differentially expressed genes in a multi-chemosensitive (G-292) versus a resistant (SJSA-1) OS cell lines. We showed that miR-34a-5p promotes the OS multi-chemoresistance
via its repression of the AGTR1 gene, a new target of miR-34a-5p.